ImmunoGen Company Profile (NASDAQ:IMGN)

About ImmunoGen (NASDAQ:IMGN)

ImmunoGen logoImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IMGN
  • CUSIP: 45253H10
  • Web:
  • Market Cap: $454.78 million
  • Outstanding Shares: 89,348,000
Average Prices:
  • 50 Day Moving Avg: $4.07
  • 200 Day Moving Avg: $2.93
  • 52 Week Range: $1.51 - $6.21
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.49
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $51.8 million
  • Price / Sales: 8.78
  • Book Value: ($1.88) per share
  • Price / Book: -2.71
  • EBIDTA: ($104,780,000.00)
  • Net Margins: -292.83%
  • Return on Assets: -60.67%
  • Debt-to-Equity Ratio: -0.79%
  • Current Ratio: 3.69%
  • Quick Ratio: 3.65%
  • Average Volume: 2.44 million shs.
  • Beta: 1.98
  • Short Ratio: 5.09

Frequently Asked Questions for ImmunoGen (NASDAQ:IMGN)

What is ImmunoGen's stock symbol?

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

How were ImmunoGen's earnings last quarter?

ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Friday, May, 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.16. The firm earned $28.70 million during the quarter, compared to analyst estimates of $16.16 million. ImmunoGen's revenue for the quarter was up 45.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.37) EPS. View ImmunoGen's Earnings History.

Where is ImmunoGen's stock going? Where will ImmunoGen's stock price be in 2017?

8 brokerages have issued twelve-month price targets for ImmunoGen's shares. Their predictions range from $1.30 to $6.00. On average, they anticipate ImmunoGen's stock price to reach $4.60 in the next twelve months. View Analyst Ratings for ImmunoGen.

What are analysts saying about ImmunoGen stock?

Here are some recent quotes from research analysts about ImmunoGen stock:

  • 1. Cantor Fitzgerald analysts commented, "IMGN’s announced sale of IMGN529 to Debiopharm for an aggregate of $55 mln provides incremental cash to the company for development of." (5/24/2017)
  • 2. Cowen and Company analysts commented, "IMGN presented data from mrive’s Phase I biopsy expansion cohort at SGO." (3/13/2017)
  • 3. According to Zacks Investment Research, "ImmunoGen reported wider-than-expected loss in quarter ending Dec 31 2016 with revenues missing estimates. However, shares of the company have outperformed the broader industry so far this year. ImmunoGen’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty and other payments. Moreover the company’s target market is ovarian cancer, represents huge potential. On the flip side, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Notably, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Hence successful development and subsequent approval of its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer), is crucial for ImmunoGen. ImmunoGen is moving to reporting on a calendar-year basis, effective Jan 1, 2017." (3/6/2017)

Are investors shorting ImmunoGen?

ImmunoGen saw a decline in short interest in April. As of April 13th, there was short interest totalling 13,612,981 shares, a decline of 8.2% from the March 31st total of 14,823,016 shares. Based on an average daily trading volume, of 1,812,708 shares, the short-interest ratio is currently 7.5 days. Currently, 16.0% of the shares of the company are sold short.

Who are some of ImmunoGen's key competitors?

Who owns ImmunoGen stock?

ImmunoGen's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.71%), Redmile Group LLC (4.46%), PRIMECAP MANAGEMENT COMPANY (4.54%), Primecap Management Co. CA (4.54%), Wells Fargo & Company MN (1.85%) and Pinnacle Associates Ltd. (1.82%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, David Brannon Johnston, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy, Nicole Onetto and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

Who sold ImmunoGen stock? Who is selling ImmunoGen stock?

ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Renaissance Technologies LLC, Wells Fargo & Company MN, Credit Suisse AG, Schwab Charles Investment Management Inc., Morgan Stanley, Alliancebernstein L.P. and Pinnacle Associates Ltd.. View Insider Buying and Selling for ImmunoGen.

Who bought ImmunoGen stock? Who is buying ImmunoGen stock?

ImmunoGen's stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, Ameriprise Financial Inc., JPMorgan Chase & Co., Bank of America Corp DE, Moloney Securities Asset Management LLC, Metropolitan Life Insurance Co. NY, Bank of New York Mellon Corp and AXA. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

How do I buy ImmunoGen stock?

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ImmunoGen stock cost?

One share of ImmunoGen stock can currently be purchased for approximately $5.09.

Analyst Ratings

Consensus Ratings for ImmunoGen (NASDAQ:IMGN) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $4.60 (9.63% downside)

Analysts' Ratings History for ImmunoGen (NASDAQ:IMGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017Cantor FitzgeraldReiterated RatingHold$5.00LowView Rating Details
5/19/2017Canaccord GenuitySet Price TargetBuy$6.00LowView Rating Details
5/18/2017Jefferies Group LLCReiterated RatingBuy$6.00HighView Rating Details
5/6/2017Cowen and CompanyReiterated RatingHoldHighView Rating Details
5/6/2017Royal Bank of CanadaSet Price TargetHold$5.00HighView Rating Details
4/19/2017Leerink SwannUpgradeMarket Perform -> Outperform$3.53 -> $3.90HighView Rating Details
3/1/2017Morgan StanleyLower Price TargetUnderweight$2.50 -> $1.30N/AView Rating Details
8/5/2016JPMorgan Chase & Co.Set Price TargetHold$9.00 -> $5.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
11/10/2015Oppenheimer Holdings Inc.Reiterated RatingBuy$24.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for ImmunoGen (NASDAQ:IMGN)
Earnings by Quarter for ImmunoGen (NASDAQ:IMGN)
Earnings History by Quarter for ImmunoGen (NASDAQ:IMGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/20173/31/2017($0.36)($0.20)$16.16 million$28.70 millionViewN/AView Earnings Details
2/17/2017Q2 2017($0.39)($0.39)$16.28 million$13.85 millionViewListenView Earnings Details
10/28/2016Q117($0.38)($0.51)$21.12 million$7.66 millionViewListenView Earnings Details
8/4/2016Q416($0.39)($0.51)$17.11 million$7.41 millionViewListenView Earnings Details
4/29/2016Q316($0.31)($0.37)$23.02 million$19.71 millionViewListenView Earnings Details
1/29/2016Q216($0.36)($0.38)$19.54 million$18.03 millionViewListenView Earnings Details
10/27/2015Q116($0.35)($0.39)$15.84 million$14.90 millionViewListenView Earnings Details
7/31/2015Q415($0.34)($0.35)$15.42 million$12.61 millionViewListenView Earnings Details
4/24/2015Q315($0.25)($0.25)$20.95 million$11.40 millionViewListenView Earnings Details
1/30/2015Q215($0.06)$0.16$37.30 million$48.30 millionViewListenView Earnings Details
10/24/2014Q115($0.14)($0.26)$21.80 million$13.20 millionViewListenView Earnings Details
8/1/2014Q414($0.36)($0.31)$9.72 million$5.74 millionViewN/AView Earnings Details
4/25/2014Q314($0.27)($0.44)$13.28 million$6.90 millionViewN/AView Earnings Details
1/31/2014Q214($0.18)($0.29)$18.16 million$30.10 millionViewListenView Earnings Details
10/25/2013Q114($0.23)($0.13)$12.10 million$17.20 millionViewN/AView Earnings Details
8/2/2013Q4 2013($0.30)($0.26)$3.44 million$3.83 millionViewN/AView Earnings Details
4/26/2013Q3 2013($0.15)($0.02)$11.94 million$25.00 millionViewN/AView Earnings Details
1/25/2013Q2 2013($0.25)($0.29)$6.02 million$2.60 millionViewN/AView Earnings Details
10/26/2012Q113($0.25)($0.30)$4.10 million$4.10 millionViewN/AView Earnings Details
8/3/2012($0.30)($0.29)ViewN/AView Earnings Details
4/27/2012($0.26)($0.24)ViewN/AView Earnings Details
1/27/2012($0.22)($0.17)ViewN/AView Earnings Details
10/27/2011($0.22)($0.26)ViewN/AView Earnings Details
8/3/2011($0.24)($0.23)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ImmunoGen (NASDAQ:IMGN)
2017 EPS Consensus Estimate: ($1.41)
2018 EPS Consensus Estimate: ($1.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.35)($0.35)($0.35)
Q3 20171($0.37)($0.37)($0.37)
Q4 20171($0.36)($0.36)($0.36)
Q1 20181($0.43)($0.43)($0.43)
Q2 20181($0.43)($0.43)($0.43)
Q3 20181($0.43)($0.43)($0.43)
Q4 20181($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)


Dividend History for ImmunoGen (NASDAQ:IMGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ImmunoGen (NASDAQ:IMGN)
Insider Ownership Percentage: 5.00%
Institutional Ownership Percentage: 85.26%
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Institutional Ownership by Quarter for ImmunoGen (NASDAQ:IMGN)
Insider Trades by Quarter for ImmunoGen (NASDAQ:IMGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Mark Alan GoldbergDirectorBuy20,000$1.80$36,000.00View SEC Filing  
11/8/2016Mark J EnyedyCEOBuy25,000$1.83$45,750.00View SEC Filing  
11/2/2016Craig BarrowsInsiderBuy10,000$1.71$17,100.00View SEC Filing  
11/2/2016Richard J GregoryVPBuy16,600$1.78$29,548.00View SEC Filing  
2/1/2016John LambertEVPSell3,889$8.22$31,967.58View SEC Filing  
1/8/2016Richard J GregoryVPSell2,369$11.10$26,295.90View SEC Filing  
1/4/2016Daniel M. JuniusCEOSell5,416$13.17$71,328.72View SEC Filing  
1/4/2016John LambertEVPSell3,889$13.20$51,334.80View SEC Filing  
12/1/2015Daniel M. JuniusCEOSell5,416$13.11$71,003.76View SEC Filing  
12/1/2015John LambertEVPSell3,889$13.11$50,984.79View SEC Filing  
11/27/2015Charles Q MorrisVPSell5,170$14.00$72,380.00View SEC Filing  
11/17/2015Dean J MitchellDirectorBuy10,000$12.51$125,100.00View SEC Filing  
11/2/2015Daniel M. JuniusCEOSell5,497$12.00$65,964.00View SEC Filing  
11/2/2015John LambertEVPSell3,889$11.73$45,617.97View SEC Filing  
10/29/2015Daniel M. JuniusCEOSell5,335$12.01$64,073.35View SEC Filing  
10/1/2015John LambertEVPSell3,889$9.55$37,139.95View SEC Filing  
9/17/2015David Brannon JohnstonCFOSell5,000$15.00$75,000.00View SEC Filing  
9/1/2015Daniel M. JuniusCEOSell5,416$13.15$71,220.40View SEC Filing  
9/1/2015John LambertEVPSell3,889$13.16$51,179.24View SEC Filing  
7/1/2015Daniel M JuniusCEOSell5,416$14.34$77,665.44View SEC Filing  
7/1/2015John LambertEVPSell3,888$14.34$55,753.92View SEC Filing  
6/15/2015Nicole OnettoDirectorSell3,211$13.86$44,504.46View SEC Filing  
6/1/2015John LambertEVPSell15,000$11.78$176,700.00View SEC Filing  
5/7/2015Daniel M JuniusCEOSell1,215$8.02$9,744.30View SEC Filing  
5/1/2015John LambertEVPSell10,000$8.32$83,200.00View SEC Filing  
11/28/2014Charles Q MorrisVPSell5,240$10.40$54,496.00View SEC Filing  
3/17/2014Daniel JuniusCEOSell15,000$16.40$246,000.00View SEC Filing  
2/26/2014Charles MorrisVPSell6,936$17.35$120,339.60View SEC Filing  
2/20/2014Charles MorrisVPSell13,672$17.10$233,791.20View SEC Filing  
2/18/2014Daniel JuniusCEOSell15,000$16.26$243,900.00View SEC Filing  
2/3/2014John LambertEVPSell4,375$14.90$65,187.50View SEC Filing  
1/22/2014Charles MorrisVPSell7,138$17.00$121,346.00View SEC Filing  
1/10/2014Theresa WingroveVPSell6,250$15.04$94,000.00View SEC Filing  
1/2/2014John LambertEVPSell4,375$14.53$63,568.75View SEC Filing  
12/10/2013Daniel JuniusCEOSell15,000$15.11$226,650.00View SEC Filing  
12/2/2013John LambertEVPSell4,375$14.70$64,312.50View SEC Filing  
11/26/2013Charles MorrisVPSell12,500$13.75$171,875.00View SEC Filing  
11/1/2013John LambertEVPSell4,375$16.41$71,793.75View SEC Filing  
9/10/2013Gregory D PerryCFOSell18,337$17.82$326,765.34View SEC Filing  
9/3/2013Daniel JuniusCEOSell16,667$16.43$273,838.81View SEC Filing  
9/3/2013John LambertEVPSell4,375$16.45$71,968.75View SEC Filing  
8/1/2013Daniel M JuniusCEOSell16,667$19.21$320,173.07View SEC Filing  
8/1/2013John LambertEVPSell4,375$19.21$84,043.75View SEC Filing  
7/11/2013James J O'learyVPSell35,000$19.02$665,700.00View SEC Filing  
7/3/2013Daniel M JuniusCEOSell16,667$17.31$288,505.77View SEC Filing  
7/1/2013John LambertEVPSell4,375$16.80$73,500.00View SEC Filing  
6/3/2013John LambertEVPSell11,250$17.20$193,500.00View SEC Filing  
5/24/2013James J O'learyVPSell28,900$18.11$523,379.00View SEC Filing  
5/1/2013John LambertEVPSell11,250$15.56$175,050.00View SEC Filing  
4/11/2013James J O'learyVPSell31,100$17.37$540,207.00View SEC Filing  
11/8/2012Mark Alan GoldbergDirectorBuy3,000$11.27$33,810.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ImmunoGen (NASDAQ:IMGN)
Latest Headlines for ImmunoGen (NASDAQ:IMGN)
DateHeadline logoImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference - May 24 at 11:35 AM logoDebiopharm International SA Enters the Field of Antibody-Drug Conjugates Through Acquisition of Phase II Asset from ImmunoGen - May 23 at 5:27 PM logoImmunoGen, Inc. (IMGN) PT Set at $6.00 by Canaccord Genuity - May 19 at 8:28 PM logoWhy ImmunoGen, Inc. Jumped Higher Today - Motley Fool - May 19 at 10:26 AM logoImmunoGen, Inc. (IMGN) Stock Rating Reaffirmed by Jefferies Group LLC - May 18 at 11:40 AM logoImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting - May 17 at 5:51 PM logoImmunoGen drug moving ahead in single-agent, combination trials - May 17 at 5:51 PM logoWhy ImmunoGen, Inc. Stock Is Flying High Today - May 15 at 4:24 PM logoImmunoGen, Inc. Begins FORWARD I, Investors Wait - May 10 at 4:30 PM logo-$0.40 EPS Expected for ImmunoGen, Inc. (IMGN) This Quarter - May 10 at 8:36 AM logoPositive News Coverage Likely to Affect ImmunoGen (IMGN) Share Price - May 9 at 12:30 AM logoImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1 - May 8 at 5:33 PM logoImmunoGen's (IMGN) "Hold" Rating Reiterated at Cantor Fitzgerald - May 8 at 10:14 AM logoImmunoGen (IMGN) Earning Somewhat Positive Press Coverage, Study Shows - May 6 at 12:33 AM logoEdited Transcript of IMGN earnings conference call or presentation 5-May-17 12:00pm GMT - May 5 at 10:54 PM logoImmunoGen (IMGN) Reports Narrower-than-Expected Loss - Nasdaq - May 5 at 5:53 PM logoImmunoGen Reports Recent Progress and First Quarter 2017 Operating Results - May 5 at 5:53 PM logoImmunoGen reports 1Q loss - May 5 at 5:53 PM logoInvestor Network: ImmunoGen, Inc. to Host Earnings Call - May 5 at 5:53 PM logoImmunoGen (IMGN) Reports Narrower-than-Expected Loss - May 5 at 5:53 PM logoImmunoGen, Inc. (IMGN) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPS - May 5 at 4:19 PM logoWhy ImmunoGen (IMGN) Might Surprise This Earnings Season - Yahoo Finance - May 4 at 6:04 PM logoWhy ImmunoGen (IMGN) Might Surprise This Earnings Season - May 4 at 6:04 PM logoHere's Why ImmunoGen Rose 10.7% in April - May 4 at 2:09 AM logoImmunoGen, Inc. (IMGN) to Release Quarterly Earnings on Friday - May 3 at 9:10 AM logoImmunoGen, Inc. (IMGN) Receives Consensus Recommendation of "Hold" from Analysts - May 2 at 10:50 PM logoSomewhat Positive Media Coverage Very Likely to Impact ImmunoGen (IMGN) Stock Price - May 2 at 5:12 PM logoIs ImmunoGen (IMGN) Poised for a Beat this Earnings Season? - May 2 at 4:20 PM logoImmunogen (IMGN) Says Results from Mirvetuximab Soravtansine Phase 1 Trail Published in Cancer - May 1 at 1:20 PM logoImmunoGen Announces Results from Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published in Cancer - May 1 at 1:20 PM logoImmunoGen (IMGN) Receiving Somewhat Favorable Media Coverage, Study Shows - April 29 at 1:42 PM logoWhen Will ImmunoGen, Inc. Finally Start Making Money? - Motley Fool - April 28 at 6:52 PM logoImmunoGen, Inc. (IMGN) Sees Significant Decrease in Short Interest - April 28 at 7:13 AM logoWhen Will ImmunoGen, Inc. Finally Start Making Money? - April 27 at 9:13 AM logoVery Positive Press Coverage Somewhat Likely to Affect ImmunoGen (IMGN) Stock Price - April 26 at 11:30 AM logoSomewhat Favorable News Coverage Likely to Affect ImmunoGen (IMGN) Stock Price - April 23 at 7:20 PM logoImmunoGen, Inc. (IMGN) Upgraded at Leerink Swann - April 23 at 7:44 AM logoImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : April 21, 2017 - April 21 at 5:48 PM logo$17.74 Million in Sales Expected for ImmunoGen, Inc. (IMGN) This Quarter - April 21 at 2:47 PM logoImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results - April 21 at 10:41 AM logoLeerink Swann Research Analysts Raise Earnings Estimates for ImmunoGen, Inc. (IMGN) - April 21 at 8:07 AM logoImmunoGen (IMGN) Getting Positive Press Coverage, AlphaOne Reports - April 20 at 9:23 PM logoUPDATE: Leerink Partners Upgrades Immunogen Inc. (IMGN) to Outperform - - April 20 at 5:58 PM logoWhy ImmunoGen, Inc. Jumped Higher Today - April 20 at 5:58 PM logoImmunoGen, Inc. breached its 50 day moving average in a Bullish Manner : IMGN-US : April 20, 2017 - April 20 at 11:29 AM logoWhy ImmunoGen, Inc. Shot Up Today - April 19 at 1:06 PM logo-$0.36 EPS Expected for ImmunoGen, Inc. (IMGN) This Quarter - April 19 at 12:25 PM logoPre-Open Stock Movers 04/19: (ARGS) (CYTR) (IMGN) Higher; (ADPT) (LBY) (IBM) Lower (more...) - April 19 at 11:27 AM logoImmunoGen's (IMGN) Buy Rating Reiterated at Jefferies Group LLC - April 18 at 7:38 AM logoPositive Press Coverage Unlikely to Affect ImmunoGen (IMGN) Stock Price - April 17 at 7:01 PM



ImmunoGen (IMGN) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff